Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investors Events
  • Pre market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
November 13, 2024 7:54 AM 2 min read

FDA Commissioner Califf Candid on Trump's Impact: 'We Just Don't Know What's Going to Happen'

by Vandana Singh Benzinga Editor
Follow

ArticleFeaturedTickersList12345!!!

FDA commissioner Robert Califf’s second term is anticipated to end in 2025, and all eyes are now on who will be the next to take the position after Donald Trump is elected president for the second time.

He was elected to head the agency in February 2022. Califf was briefly the agency’s commissioner under the Obama administration beginning in 2016.

At a conference hosted by the Friends of Cancer Research, Califf acknowledged the uncertainty President-elect Donald Trump’s return to the White House raises for the agency workforce.

He is “disappointed” about the election’s outcome. “I think we just don’t know what’s going to happen.”

At the Tuesday conference, Califf added, “The gist of this administration, from everything that’s been said, is that they want to change a lot of things, and how it gets changed depends on who gets appointed into key positions and how the various policies play out.”

Also Read: Donald Trump’s Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare

Asked whether FDA employees are eying the exits, Califf said, “people are waiting to see.”

Asked to respond to Robert F. Kennedy Jr’s statements about clearing FDA groups focused on nutrition and other issues, Califf suggested the agency is limited in addressing issues with the American diet because of Congress.

In an interview Califf said, “In times of change and chaos, there’s also opportunity,” he continued. “I will just comment, there’s a lot of things that I bet almost everyone in leadership positions in the health agencies would have liked to have changed but couldn’t because of the gridlock of various interests that made it difficult to change things.”

Callif said he believes the FDA is at “peak performance right now — and we’ll see what happens as the new team comes in.”

“From things that have been said, the change could happen internally or from external decisions made by the administration,” he said. “I just think we have to wait and see and have some faith that hard-working, high-quality people are still going to be in place and have support from — I hope — the external regulated community, which given the dynamics is likely to be the most important factor.”

While Califf hasn’t officially announced his departure from the FDA, he said today that “this is not the first time I’ve ridden out of town after an election.”

Read Next:

  • Netflix Reaches 70 Million Users On Ad-Supported Plan, Boosts Live Sports Ads

Image via Adobe Stock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.


Posted In:
BiotechGovernmentNewsRegulationsHealth CareFDATop StoriesGeneralBriefsStories That Matter
FXH Logo
FXHFirst Trust Health Care AlphaDEX
$114.720.35%
Overview
IHE Logo
IHEiShares U.S. Pharmaceutical ETF
Not Available-%
IYH Logo
IYHiShares U.S. Healthcare ETF
Not Available-%
PJP Logo
PJPInvesco Pharmaceuticals ETF
Not Available-%
PTH Logo
PTHInvesco Dorsey Wright Healthcare Momentum ETF
$48.52-1.68%
SPY Logo
SPYState Street SPDR S&P 500 ETF Trust
$697.020.23%
VHT Logo
VHTVanguard Health Care ETF
$288.18-0.29%
FXH Logo
FXHFirst Trust Health Care AlphaDEX
$114.720.35%
Overview
IHE Logo
IHEiShares U.S. Pharmaceutical ETF
Not Available-%
IYH Logo
IYHiShares U.S. Healthcare ETF
Not Available-%
PJP Logo
PJPInvesco Pharmaceuticals ETF
Not Available-%
PTH Logo
PTHInvesco Dorsey Wright Healthcare Momentum ETF
$48.52-1.68%
SPY Logo
SPYState Street SPDR S&P 500 ETF Trust
$697.020.23%
VHT Logo
VHTVanguard Health Care ETF
$288.18-0.29%
Comments
Loading...